Xpovio (selinexor) / Karyopharm, Antengene, Menarini, NeoPharm, FORUS Therapeutics, Jiangsu Hansoh Pharma, PharmaEssentia, Boryung Group - LARVOL DELTA

CERVINO: A Randomized Phase 3 Study of Etentamig vs Investigator's Choice of Standard Available Therapies in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Triple-Class Exposure (IMS 2026) - P3 | "Pts were randomized 1:1 to Etenta Q4W or SAT (carfilzomib + dexamethasone [Kd], elotuzumab + pomalidomide + d [EloPd], or selinexor + bortezomib + d [SVd]). In heavily pretreated pts with triple-class exposed RRMM, Etenta significantly improved ORR and PFS vs SAT, with an early positive OS signal. A single SUD andQ4Wdosing from initiation were associated with very low rates of CRS, ICANS, and ≥ G3 infections, reinforcing Etenta’s best-in-class safety potential. Data support Etenta monotherapy as a new standard of care with convenient dosing suitable for global outpatient and community use."

Clinical • Late-breaking abstract • P3 data • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial. (PubMed, Br J Haematol) - P3 | "Selinexor-R maintenance did not improve PFS and substantially increased toxicity. Selinexor-R maintenance cannot be recommended for the general myeloma population; we did not observe a benefit among high-risk disease."

Journal • P3 data • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology • Transplantation

LONG-TERM FOLLOW-UP OF SELINEXOR MAINTENANCE TREATMENT IN PATIENTS WITH TP53 WILD TYPE ADVANCED/RECURRENT ENDOMETRIAL CANCER: INTERMEDIATE ENDPOINTS BY MISMATCH REPAIR STATUS IN THE ENGOT-EN5/GOG-3055/SIENDO STUDY (IGCS 2025) - P3 | "As of April 2024, 50% of patients in the TP53wt subgroup discontinued selinexor and initiated subsequent therapy vs 83% in placebo. Median TFST was 31.7 months in selinexor vs 10.6 months in placebo (HR 0.41, p=0.0002). Median PFS2 and TSST were both not reached (NR) in selinexor vs 35.2 and 22.1 months, respectively, in placebo (HR 0.62, p=0.0581; HR 0.47, p= 0.0041)."

Clinical • Metastases • Mismatch repair • Endometrial Cancer • Oncology • Solid Tumor • TP53

Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment. (ASCO 2023) - P1b/2, P2b, P3 | " We analyzed the effectiveness of non-cellular αBCMA (NCA) therapies in pts with MM treated in 4 clinical studies (STORM [NCT02336815]; STOMP [NCT02343042]; BOSTON [NCT03110562], XPORT-MM-028 [NCT04414475]) with selinexor + dexamethasone (Xd), with or without PIs, IMiDs, or αCD38 mAbs, followed by therapy with NCA...Thirty-seven pts (median age: 68, range: 40-87) received NCA therapy at any time following a selinexor regimen (Xd, n = 12; Xd + bortezomib, n = 9; Xd + pomalidomide, n = 6; Xd + daratumumab, n = 3; Xd + carfilzomib, n = 5; Xd + ixazomib, n = 2). NCAs included the ADC belantamab mafodotin (n = 28), the BiS teclistamab (n = 2), SEA-BCMA (n = 2), AMG 701 (n = 1), elranatamab (n = 1), MEDI2228 (n = 1), and investigational (n = 3; 2 had αBCMA bispecific antibodies and 1 had αBCMA BITE) (1 pt received 2 NCAs, belantamab and teclistamab)... In this cohort of heavily-pretreated pts with MM who received a selinexor regimen prior to NCA, overall..."

Hematological Malignancies • Immune Modulation • Multiple Myeloma • Oncology

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - P2 | N=58 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2026 ➔ Sep 2027 | Trial primary completion date: Sep 2026 ➔ Apr 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • MYC

The Efficacy and Safety of Gecacitinib in Combination with Selinexor Treated intermediate or high-risk Myelofibrosis Patients (ChiCTR) - P2 | N=42 | Not yet recruiting | Sponsor: The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University

New P2 trial • Myelofibrosis • JAK2

Selinexor plus tislelizumab in patients with relapsed/refractory NK/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial. (PubMed, Oncologist) - P1/2 | "Selinexor plus tislelizumab demonstrated manageable toxicity and substantial activity in patients with relapsed/refractory NKTCL previously treated with CPI, supporting further evaluation of nuclear export inhibition as a strategy to re-engage antitumor immunity after failure of PD-1 blockade."

Journal • P1 data • Hematological Disorders • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • XPO1

Selinexor, Mezigdomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Relapsing / Ineligible for T-Cell-Redirecting Therapy (TCRT): STOMP Phase 1 Preliminary Results (IMS 2026) - P1/2 | "Three pts relapsed after TCRT (3 cilta-cel; 2 talquetamab; 1 IGM-2644) and 4 after belantamab mafodotin, with 3 pts refractory to B-cell maturation antigen–targeted therapy. For the SMd all-oral combination, TEAEs were consistent with AE profiles for S and M, and no new safety signals were detected. The DLT of G4 neutropenia was manageable with filgrastim and dose reduction. Across all dose levels SMd showed efficacy in pts with heavily pretreated RRMM in whom TCRT had failed or who could not receive TCRT."

Clinical • IO biomarker • P1 data • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Leukopenia • Multiple Myeloma • Neutropenia • Targeted Protein Degradation • Thrombocytopenia • CCR7 • CRBN • TIGIT • XPO1

Selinexor Treatment Upregulates BCMA and Increases Belamaf Sensitivity in Bcma-Low Cell Line Models (IMS 2026) - "Introduction: Selinexor (Seli), an exportin 1 inhibitor, is approved in combination with bortezomib and dexamethasone for relapsed/refractory multiple myeloma (MM). Our findings demonstrate that Seli induces a robust upregulation of BCMA receptor density in MM cell models, as quantified by d STORM and supported by increased BCMA gene expression. This enhanced surface expression was associated with increased sensitivity to Belamaf in AMO1 cells, suggesting that Seli may be especially effective as a sensitizing agent in BCMA-low contexts."

IO biomarker • Preclinical • Hematological Malignancies • Multiple Myeloma • XPO1

Risk-Directed Front-Line Therapy for Newly Diagnosed Multiple Myeloma (NDMM) Incorporating Selinexor - the RIDDLE-MX Trial Amarc 21-04. (IMS 2026) - P2 | " RIDDLE-MX (ACTRN12622001366741) is an Australian Myeloma Research Consortium (AMaRC) SKY92 MMProfiler risk-directed, multi-site study exploring novel quadruplet induction with 4, 35-day cycles of 1.3mg/m 2 bortezomib (V) SC weekly, 25mg lenalidomide (R) PO D1-21, 40mg dexamethasone(d) PO weekly and 40mg weekly selinexor (X) PO weekly in HR NDMM prior to high-dose therapy (HD) + ASCT, 2 cycles X-VRd consolidation and maintenance comprising X 40mg weekly, R 10mg daily (X-R) to disease progression (PD). RIDDLE-MX explored SKY92 MMprofiler risk-directed X-VRd induction, ASCT, consolidation and X-R maintenance in HR NDMM patients. Centralised SKY92 testing successfully facilitated risk-directed therapy at sites throughout Australia, providing rapid identification of HR pts. Whilst ORR and preliminary estimation of PFS are promising, rates of sustained MRD negativity were low in this HR NDMM population."

Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • TP53

Real-World Efficacy and Safety of Selinexor, Bortezomib, and Dexamethasone (Svd) Utilizing a Novel Dose Ramp-Up Strategy in Lenalidomide-Refractory Multiple Myeloma (IMS 2026) - "Antiemetic prophylaxis with ondansetron was mandated for all patients. A selinexor dose ramp-up approach, coupled with routine antiemetic prophylaxis, radically improves the tolerability profile of the SVd regimen, effectively eliminating nausea and minimizing high-grade thrombocytopenia. In a difficult-to-treat, lenalidomide-refractory population, this optimized dosing strategy yielded a 100% ORR ( with 4/8 achieving CR ), substantially outperforming the 67.9% ORR seen in the BOSTON trial's lenalidomide-refractory cohort. Furthermore, positioning SVd in anti-CD38-naive patients fills a critical clinical gap, offering a highly effective, tolerable, and innovative sequencing approach for early RRMM, including reliable utility as a bridge to ASCT."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Cardiovascular • Coronary Artery Disease • Heart Failure • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Myocardial Infarction • Thrombocytopenia

Phase 2 Study of Selinexor, Carfilzomib, and Dexamethasone in Early Relapsed or Refractory Multiple Myeloma Previously Treated with 1-2 Prior Lines of Therapy (IMS 2026) - "Len-refractory disease was present in 42 pts (87.5%), and 25 (52.1%) were refractory to both len and bortezomib. XKd demonstrated clinically meaningful and durable responses with manageable AEs in early RRMM despite the high prevalence of len-refractory disease. Outcomes appeared more favorable in pts without adverse biologic or functional high-risk features, suggesting that risk stratification may remain important for optimizing treatment outcomes even in early RRMM."

P2 data • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Respiratory Diseases • Thrombocytopenia

Outcomes of Triple-Class Exposed Relapse/Refractory Multiple Myeloma Patients Treated with Carfilzomib-Based Regimens: Real-World, Single Center Study (IMS 2026) - " This retrospective, single-center cohort study included all consecutive TCE RRMM pts (defined as progressed after proteasome inhibitor [PI], Immunomodulatory agent [IMiD] and daratumumab [DARA]) who received ≥1 dose of K, either with dexamethasone alone (Kd) or in triplet combinations...K regimens included Kd monotherapy (27%), Kd+ cyclophosphamide (KCyd, (30%), Kd+ pomalidomide (KPd, 25%), Kd+DARA (11%), and others (selinexor, lenalidomide, venetoclax)... K-based therapy was safe and effective in TCE RRMM pts. R-ISS score, lower K dose, frailty and prior IMiD refractoriness predict shorter PFS. Combination had no advantage over monotherapy."

Clinical • Real-world • Real-world evidence • CNS Disorders • Epilepsy • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases • Thrombocytopenia

Genotype-Informed Single-Cell Rna-Seq Resolves Functional Subclonal Heterogeneity in Multiple Myeloma (IMS 2026) - "WNN subclones were compared with RNA-only clusters using silhouette score, within-cluster CNA variance, and clone-level signatures, including GEP70 risk, IMiD-resistance, and Selinexor-response as proof-of-principle therapy-associated programs... WNN integration of scRNA-seq-derived expression, CNA, and SNV features links high-risk genomic lesions to transcriptional-risk and therapy-associated states at single-cell resolution. This approach complements bulk genomics by showing that genomic and transcriptional risk can be partially decoupled within tumors, providing a practical strategy to dissect functional subclonal heterogeneity in MM."

Heterogeneity • Hematological Malignancies • Multiple Myeloma • SDC1

Feasibility and Efficacy of Intensive Chemotherapy-Based Holding and Bridging Therapy Prior to BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (IMS 2026) - "Regimens included VdT-PACE (n=6), Kd-PACE (n=4), (P)ACE-based combinations (d-ACE, d-PACE, P-PACE, mini-PACE; (n=5)), IsaKd-PACE and a Selinexor-based regimen (SVd-PACE)... IC with PACE-like regimens was applied preferentially in high-TB/EMD pts and achieved a CAR-T ORR of 90%. Achieving ≥ VGPR was consistently associated with substantially reduced CAR-T toxicities. IC prior to lymphocyte apheresis did not impair CAR-T manufacturing or CAR-T efficacy."

CAR T-Cell Therapy • Clinical • CNS Disorders • Cognitive Disorders • Developmental Disorders • Hematological Malignancies • Multiple Myeloma

Efficacy and Safety of Aponermin (Rhtrail)-Kd-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Analysisultiple Myeloma, a Single-Center Retrospective Study (IMS 2026) - "Combined with carfilzomib and dexamethasone, aponermin may sensitize resistant clones to DR-mediated cell death... Between May 2024 and February 2026, we retrospectively analyzed RRMM patients treated with ApoKd-based regimens (±selinexor or chemotherapy)... In this heavily pre-treated cohort characterized by high rates of EMD and triple-class prior exposure, ApoKd-based regimens achieved an ORR of 64.1% and a median PFS of 6.8 months. Notably, the depth of response appeared independent of triple-class exposure history, and the regimen demonstrated comparable activity in patients with and without EMD. The toxicity profile was predominantly hematologic and manageable."

Retrospective data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukopenia • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases • Thrombocytopenia

Dose-Optimized Selinexor-Based Regimens in Plasmacytoma-Associated Relapsed/Refractory Multiple Myeloma: Real-World Imaging and Treatment Persistence Outcomes (IMS 2026) - "Patients received selinexor combined with proteasome inhibitor (PI)-based, IMiD-based, anti-CD38-based regimens, or selinexor-dexamethasone according to physician discretion. Selinexor-based regimens demonstrated clinically meaningful activity in this real-world RRMM cohort, including encouraging imaging responses in plasmacytoma-associated disease. Despite frequent dose modifications, durable ongoing treatment exposure was observed in selected patients, supporting individualized dose-optimization approaches in difficult-to-treat RRMM populations."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Plasmacytoma

Comparative Efficacy of Elotuzumab, Pomalidomide, and Dexamethasone vs Standard Care Triplets in Relapsed/Refractory Multiple Myeloma After at Least One Prior Line of Therapy: A Network Meta-Analysis (IMS 2026) - "Assuming equivalence ( collapsed node s ) between pomalidomide – dexamethasone (Pd) and bortezomib – dexamethasone ( Vd ), and between carfilzomib – dexamethasone ( Kd ) and lenalidomide – dexamethasone (Rd), EPd showed no statistically significant difference in PFS versus any of the eight comparator triplet regimens ; HRs ( 95% CrIs ) ranged from 0.81 ( 0.43 – 1.54 ) versus selinexor – Vd to 1.39 ( 0.69 – 2.85 ) versus daratumumab (D )– Kd , with all CrIs crossing 1. This NMA found no statistically significant differences in PFS between EPd and other approved or guideline-recommended triplet regimens in patients with RRMM with ≥1 prior line of therapy, any prior R exposu re , and no prior anti-CD38 exposure . Results were consistent in the R-refractory sub group across alternative pooled doublet scenarios, supporting EPd as a n appropriate control among SOC options . Ongoing trials including EPd in anti-CD38 – exposed/refractory populations may help further..."

Retrospective data • Hematological Malignancies • Multiple Myeloma

Clinical Efficacy and Safety of Epronermin Plus Selinexor (CPT+S) in Newly Diagnosed Ultra-Frail Patients with Multiple Myeloma (IMS 2026) - "For NDMM patients intolerant or predicted intolerant to standard therapies, CPT+S is a highly valuable de-escalated transitional strategy. With a 57.1% ORR and excellent safety, it effectively reduces tumor burden and improves patient fitness, enabling a bridge to standard sequential therapies. However, efficacy remains limited in patients with both high-risk cytogenetics and irreversible acute organ failure, highlighting the need for alternative early interventions in this specific subgroup."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Infectious Disease • Multiple Myeloma • TP53

Characteristics and Outcomes of Central Nervous System Multiple Myeloma (IMS 2026) - "Pts received a median of 4 (R:1-16) doses of IT therapy, 4/5 received thiotepa (2 in combination with methotrexate & cytarabine, & mercaptopurine respectively), & 1 received methotrexate alone. Systemic treatment included combination of proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, selinexor, & other novel therapeutics (1 received ciltacabtagene autoleucel (ciltacel), & another received talquetamab followed by teclistamab)...Pts with CSF clearance (2/5) had received ciltacel & VD-PACE, while 2/5 with radiographic response had received ciltacel & daratumumab-pomalidomide... CNS myeloma pts had a dismal prognosis. All pts relapsed within 30m of ASCT, pointing to functionally high-risk disease. This highlights the need for increased awareness for early identification & CNS directed therapies."

CNS Disorders • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

A Multicenter Real-World Study: Efficacy and Outcomes of Selinexor Combined with Pomalidomide and Dexamethasone (Xpd) in the Treatment of Multiple Myeloma with Central Nervous System Involvement (IMS 2026) - "Prior to XPd treatment, 4 patients (40%) had been exposed to bortezomib, lenalidomide/pomalidomide, and anti-CD38 monoclonal antibody (daratumumab), and 2 patients (20%) had undergone autologous stem cell transplantation (ASCT). The XPd regimen demonstrated improved outcomes compared with historical controls in patients with CNS-MM, providing a therapeutic option, although it is not curative. More effective treatment strategies are warranted, including combination approaches with BCMA-targeted therapies and novel immunotherapies, to achieve deeper and more durable responses."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

Functional Precision Medicine Using Ex Vivo Drug Sensitivity Profiling to Guide Therapy Selection in Relapsed/Refractory Multiple Myeloma: Results of a Prospective Clinical Trial (IMS 2026) - P=N/A | "Prior exposure included lenalidomide (100%), bortezomib (97.5%), carfilzomib (85%), daratumumab (82%), pomalidomide (77.5%), and BCMA CAR-T (12.5%). Top-ranked agents by DSS in v1 included bortezomib (median DSS 47.7), carfilzomib (47.3), panobinostat (47.0), and romidepsin (45.4). In v2, leading agents were marizomib ( 46.1), carfilzomib (40.2), ixazomib (37.2), and oprozomib (31.6)...ROC analysis for bortezomib (n=12) and selinexor (n=8) yielded AUCs of 0.471 and 0.462, respectively... High-throughput drug sensitivity testing was feasible in heavily pretreated RRMM and generated actionable results in nearly all patients. DSS-based prediction varied across agents, highlighting the need for drug-specific thresholds and larger validation cohorts. These findings support further development of functional precision medicine as a complementary tool to refine therapeutic decision-making in RRMM"

Late-breaking abstract • Preclinical • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia • Plasmacytoma • SDC1

Ferroptosis Resistance Mediates Selinexor Resistance in Multiple Myeloma via MTCH1-Dependent Disruption of Mitochondria-Associated Endoplasmic Reticulum Membranes (IMS 2026) - "Our study identifies a previously unrecognized MTCH1–MFN2–MAM regulatory axis controlling ferroptosis susceptibility in selinexor-resistant MM. MTCH1-mediated disruption of ER–mitochondria communication preserves mitochondrial homeostasis and suppresses ferroptotic cell death, thereby promoting therapeutic resistance. Targeting MAM dysfunction and restoring ferroptotic sensitivity may represent a novel strategy to overcome selinexor resistance in MM."

Late-breaking abstract • Hematological Malignancies • Multiple Myeloma • MFN2

Longer-Term Safety And Efficacy Of Selinexor Maintenance Therapy For Patients With TP53wt Advanced Or Recurrent Endometrial Cancer: Follow-Up Subgroup Analysis Of The ENGOT-EN5/GOG-3055/SIENDO Study (ESGO 2025) - P3 | "Strong PFS signals were observed regardless of MMR status, particularly in the TP53wt/pMMR subgroup, a patient population with high unmet need. A phase 3 trial is underway to further investigate the safety and efficacy of selinexor as maintenance therapy in patients with advanced/recurrent TP53wt EC (NCT05611931)."

Clinical • Metastases • Endometrial Cancer • Oncology • Solid Tumor • TP53

Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial. (PubMed, J Immunother Precis Oncol) - P1 | "We included 10 patients with uveal melanoma who received treatment with either selinexor plus pembrolizumab (n = 9) or selinexor plus nivolumab and ipilimumab (n = 1). Clinical benefit was achieved in most patients and should be validated in larger phase 2 trials. ClinicalTrials.gov ID: NCT02419495."

Checkpoint inhibition • Journal • P1 data • Cardiovascular • Eye Cancer • Heart Failure • Leukopenia • Melanoma • Neutropenia • Solid Tumor • Thrombocytopenia • Uveal Melanoma